帕金森升高:改善健康的延伸
Kathleen E McKee1, Miriam R Rafferty2,3, Theadora W Sakata1,4,5
1Department of Neurology, Intermountain Medical Center Neurosciences Institute, Intermountain Health, Salt Lake City, UT, United States.
Frontiers in sports and active living
|June 18, 2025
概括
本研究提出了一个主动的,基于价值的保健模式,用于帕金森病 (PD) 使用综合实践单元 (IPU). IPU专注于基于证据的运动,以减缓疾病的进展,并改善PD患者的健康状况.
科学领域:
- 神经学 神经学
- 医疗保健管理的管理
- 运动科学 运动科学
背景情况:
- 帕金森病 (PD) 的管理是反应性的,错过了维持患者健康的机会.
- 目前对患有PD (PwP) 的人的护理没有充分解决这种疾病的渐进性.
- 需要采取积极的方法来改善普华永道的健康状况.
研究的目的:
- 概述一个主动的,以价值为基础的PD医疗保健模式的愿景.
- 为PD护理引入以患者为中心的综合实践单位 (IPU).
- 为了证明综合性PD护理和炼干预措施的财务可持续性.
主要方法:
- 建立一个专门的帕金森病初级保健医生领导的IPU.
- 实施一个基于证据的,心率驱动的高强度有氧运动计划.
- 整合阻力,灵活性和平衡练习.
- 针对中度至重度PD阶段的精心策划的康复服务.
主要成果:
- 预计通过综合护理和疾病减缓干预措施改善健康状况.
- 通过完全资本化,风险共享模式实现财务可持续性的潜力.
- 为普华永道 (PwP) 证明改善了护理质量和成本.
结论:
- 综合实践单位 (IPU) 模型可以为帕金森病提供主动的,以患者为中心的护理.
- 基于证据的运动是减缓PD进展和改善健康的关键干预措施.
- 基于价值的,资本化的模式可以确保专门的PD护理的财务可持续性.
相关概念视频
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K


